Search results for "THROMBOEMBOLISM"

showing 10 items of 208 documents

Incidence, risk factors, clinical characteristics and outcomes of deep venous thrombosis in patients with COVID-19 attending the Emergency Department…

2021

Background and importance A higher incidence of venous thromboembolism [both pulmonary embolism and deep vein thrombosis (DVT)] in patients with coronavirus disease 2019 (COVID-19) has been described. But little is known about the true frequency of DVT in patients who attend emergency department (ED) and are diagnosed with COVID-19. Objective We investigated the incidence, risk factors, clinical characteristics and outcomes of DVT in patients with COVID-19 attending the ED before hospitalization. Methods We retrospectively reviewed all COVID patients diagnosed with DVT in 62 Spanish EDs (20% of Spanish EDs, case group) during the first 2 months of the COVID-19 outbreak. We compared DVT-COVI…

MaleDeep veinComorbidity030204 cardiovascular system & hematologyChest pain0302 clinical medicineRisk Factorsrisk factorsclinical characteristicsIncidenceIncidence (epidemiology)Age FactorsVenous ThromboembolismMiddle AgedPulmonary embolismVenous thrombosismedicine.anatomical_structureEmergency MedicineoutcomeFemalemedicine.symptomEmergency Service Hospitalsevere acute respiratory syndrome coronavirus 2Adultmedicine.medical_specialtyRisk Assessment03 medical and health sciencescoronavirus disease 2019Internal medicineThromboembolismmedicineHumanscardiovascular diseasesTromboembolismeAgedRetrospective Studiesdeep venous thrombosisbusiness.industryCOVID-19030208 emergency & critical care medicineRetrospective cohort studyOriginal ArticlesEmergency departmentOdds ratiomedicine.diseaseSpainCase-Control StudiesincidencePulmonary Embolismbusiness
researchProduct

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

2013

International audience; BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. METHODS: We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg onc…

MaleMESH: Factor Xa[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRivaroxabanRandomized controlled triallawMedicineMESH: Double-Blind Method030212 general & internal medicineMESH: AgedMESH: Middle AgedVenous ThromboembolismGeneral MedicineMiddle AgedMESH: Thiophenes3. Good healthAnesthesiaAcute DiseaseMESH: Administration OralMESH: Acute DiseaseFemaleMESH: Hemorrhagemedicine.drugAdultRandomizationMESH: EnoxaparinInjections SubcutaneousMorpholinesMESH: MorpholinesHemorrhageThiophenesMESH: AnticoagulantsMESH: Drug Administration SchedulePlaceboDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodRivaroxaban venous thromboembolismHumansEnoxaparinAgedRivaroxabanMESH: Humansbusiness.industryMESH: Injections SubcutaneousAnticoagulantsMESH: AdultConfidence intervalMESH: MalechemistryBetrixabanRelative riskbusinessVenous thromboembolismMESH: FemaleFactor Xa Inhibitors
researchProduct

Estimated Glomerular Filtration Rate Is an Easy Predictor of Venous Thromboembolism in Cancer Patients Undergoing Platinum-Based Chemotherapy

2014

Abstract Background. Reduced estimated glomerular filtration rate (eGFR) has been associated with increased venous thromboembolism (VTE) risk in the general population. VTE incidence significantly increases in cancer patients, especially those undergoing chemotherapy. Despite the evidence that a substantial number of cancer patients have unrecognized renal impairment, as indicated by reduced eGFR in the presence of serum creatinine levels within the reference value, chemotherapy dosage is routinely adjusted for serum creatinine values. Among chemotherapies, platinum-based regimens are associated with the highest rates of VTE. A cohort study was designed to assess the value of pretreatment e…

MaleOncologyCancer ResearchSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPlatinum CompoundsPlatinum-based chemotherapy; Renal impairment; Risk prediction; Risk stratification; Toxicity; Venous thromboembolism; Adult; Aged; Aged 80 and over; Antineoplastic Agents; Cohort Studies; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Neoplasms; Platinum Compounds; Venous Thromboembolism; Young Adult; Cancer Research; Oncology; Medicine (all)Platinum CompoundKidneyAntineoplastic AgentCohort Studieschemistry.chemical_compoundNeoplasmsRenal impairmentPlatinum-based chemotherapyAged 80 and overeducation.field_of_studyMedicine (all)Hazard ratioVenous ThromboembolismMiddle AgedRisk predictionOncologySymptom Management and Supportive CareCreatinineCohortFemaleHumanGlomerular Filtration RateCohort studyAdultmedicine.medical_specialtyPopulationRenal functionAntineoplastic AgentsYoung AdultInternal medicinemedicineHumanscardiovascular diseaseseducationRisk stratificationAgedChemotherapyCreatinineToxicitybusiness.industryCancerRenal impairment; Risk stratification; Venous thromboembolism; Risk prediction; Toxicity; Platinum-based chemotherapymedicine.diseaseSurgerychemistryNeoplasmCohort StudiebusinessThe Oncologist
researchProduct

Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.

2016

Venous thromboembolism (VTE) is common in cancer patients. However, little is known about VTE risk in metastatic urothelial carcinoma or variant histologies (UC/VH). We sought to characterize the incidence, associative factors, including whether various chemotherapy regimens portend different risk, and impact of VTE on survival in metastatic UC/VH patients. Patients diagnosed with metastatic UC/VH from 2000 to 2013 were included in this multicenter retrospective, international study from 29 academic institutions. Cumulative and 6-month VTE incidence rates were determined. The association of first-line chemotherapy (divided into six groups) and other baseline characteristics on VTE were anal…

MaleOncologyCancer Researchmedicine.medical_treatmentDisease030204 cardiovascular system & hematologyDeoxycytidine0302 clinical medicineNeoplasm MetastasisOriginal ResearchIncidenceIncidence (epidemiology)Middle AgedPrognosis3. Good healthOncology030220 oncology & carcinogenesischemotherapy survivalbladder cancerFemaleBufeta -- Càncermedicine.drugAdultmedicine.medical_specialtyMetastatic Urothelial Carcinomavenous thromboembolismAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInternal medicineUrothelialmedicineHumansRadiology Nuclear Medicine and imagingcardiovascular diseasesAgedRetrospective StudiesTrombosi -- TractamentGynecologyCisplatinCarcinoma Transitional CellChemotherapyBladder cancerbusiness.industryClinical Cancer ResearchCancermedicine.diseaseequipment and suppliesSurvival AnalysisGemcitabineGemcitabineUrinary Bladder NeoplasmsUrothelial;Cisplatinbusiness
researchProduct

e-Health-based management of patients receiving oral anticoagulation therapy: results from the observational thrombEVAL study

2017

Essentials e-Health based health care by an expert centre may advance management of oral anticoagulation. Outcome of patients was compared between an e-health based coagulation service and regular care. Patients in the coagulation service cohort experienced a significantly better clinical outcome. Lower risk for adverse events was related to anticoagulation-specific and non-specific outcome. SummaryBackground Management of oral anticoagulation (OAC) therapy is essential to minimize adverse events in patients receiving vitamin K-antagonists (VKAs). Data on the effect of e-health-based anticoagulation management systems on the clinical outcome of OAC patients are limited. Objectives To compar…

MalePediatricsVitamin KAdministration OralComorbidity030204 cardiovascular system & hematologyRate ratioSERVICE0302 clinical medicineRisk FactorsGermanyUSUAL MEDICAL-CAREClinical endpointProspective Studies030212 general & internal medicineAged 80 and overOUTCOMESHazard ratioDABIGATRANHematologyMiddle AgedHospitalizationTreatment OutcomeCohortdelivery of healthcareFemaleepidemiologyPatient SafetytelemedicineCohort studymedicine.drugmedicine.medical_specialtyanticoagulantsHemorrhageLower riskpatient outcome assessmentWARFARIN03 medical and health sciencesThromboembolismmedicineNONVALVULAR ATRIAL-FIBRILLATIONHumansQUALITYInternational Normalized RatioAdverse effectBlood CoagulationMETAANALYSISAgedProportional Hazards ModelsRivaroxabanbusiness.industrySTROKE PREVENTIONRIVAROXABANbusinessFollow-Up Studies
researchProduct

Validation of STA-Liatest D-Di assay for exclusion of pulmonary embolism according to the latest Clinical and Laboratory Standard Institute/Food and …

2017

: Combined clinical pretest probability (PTP) and D-dimer testing have great diagnostic value for pulmonary embolism exclusion. To harmonize performance levels of D-dimer assays available on the market, the Clinical and Laboratory Standard Institute (CLSI) has published a guideline, endorsed by the US Food and Drug Administration (FDA). Such guideline specifies the ideal D-dimer assay characteristic and target population. This study was conducted following the CLSI guideline to upgrade the assay-intended use and obtain FDA clearance of STA-Liatest D-Di assay for pulmonary embolism exclusion in patient with low/moderate PTP. This was an international, multicenter, prospective nonrandomized, …

MalePediatricsmedicine.medical_specialtypulmonary embolism030204 cardiovascular system & hematologyFood and drug administrationFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicinemedicineHumans030212 general & internal medicineProspective StudiesSTA-Liatest D-Dibusiness.industryUnited States Food and Drug AdministrationClinical and Laboratory Standard InstituteFood and Drug AdministrationHematologyGeneral MedicineGuidelineOriginal ArticlesMiddle Agedmedicine.diseaseThrombosisConfidence intervalUnited StatesPulmonary embolismPre- and post-test probabilityD-dimerEmergency medicineAmbulatoryBiological AssayFemalebusinessVenous thromboembolismBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Incidence and Clinical Impact of Recurrent Takotsubo Syndrome: Results From the GEIST Registry

2019

Background Current literature only reports variable information from single‐center studies on the recurrence rate, the complications, and the outcome of patients with Takotsubo syndrome ( TTS) experiencing recurrent TTS . Therefore, a detailed description of clinical characteristics, predictors, and the prognostic impact of patients with TTS and recurrences in a multicenter registry is needed. Methods and Results We analyzed 749 patients with TTS from 9 European centers being part of the international, multicenter GEIST (German Italian Stress Cardiomyopathy) Registry. Patients were divided into the recurrence group and the nonrecurrence group. The recurrence rate at a median follow‐up of 8…

MalePediatricsmedicine.medical_specialtyrecurrenceCardiomyopathyVentricular Dysfunction RightShock Cardiogenic030204 cardiovascular system & hematology03 medical and health sciencesVentricular Dysfunction Left0302 clinical medicineTakotsubo CardiomyopathyGermanyThromboembolismMedicineHumans030212 general & internal medicineHospital MortalityRegistriesOriginal ResearchAgedProportional Hazards ModelsHeart FailureAged 80 and overTakotsubo syndromebusiness.industryIncidence (epidemiology)IncidenceStroke VolumeMiddle Agedmedicine.diseaseStrokeItalyBackground currentHeart failureHypertensionFemaleCardiology and Cardiovascular MedicinebusinessJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
researchProduct

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The …

2010

Background: Contemporary clinical risk stratification schemata for predicting stroke and thromboembolism (TE) in patients with atrial fibrillation (AF) are largely derived from risk factors identified from trial cohorts. Thus, many potential risk factors have not been included. Methods: We refined the 2006 Birmingham/National Institute for Health and Clinical Excellence (NICE) stroke risk stratification schema into a risk factor-based approach by reclassifying and/or incorporating additional new risk factors where relevant. This schema was then compared with existing stroke risk stratification schema in a real-world cohort of patients with AF (n = 1,084) from the Euro Heart Survey for AF. R…

MalePrognosiIncidenceRisk FactorReproducibility of ResultRisk AssessmentFollow-Up StudieEuropeStrokeRetrospective StudiePopulation SurveillanceThromboembolismAtrial FibrillationFemaleAgedHuman
researchProduct

Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism

2019

Abstract Patients with isolated pulmonary embolism (PE) have a distinct clinical profile from those with deep vein thrombosis (DVT)-associated PE, with more pulmonary conditions and atherosclerosis. These findings suggest a distinct molecular pathophysiology and the potential involvement of alternative pathways in isolated PE. To test this hypothesis, data from 532 individuals from the Genotyping and Molecular Phenotyping of Venous ThromboEmbolism Project, a multicenter prospective cohort study with extensive biobanking, were analyzed. Targeted, high-throughput proteomics, machine learning, and bioinformatic methods were applied to contrast the acute-phase plasma proteomes of isolated PE pa…

MaleProteomeDatasets as TopicComorbidity030204 cardiovascular system & hematologyProteomicsBioinformaticsBiochemistryThrombosis and HemostasisMachine LearningPathogenesis0302 clinical medicineProtein-Arginine Deiminase Type 2Prospective StudiesProtein Interaction MapsProspective cohort study0303 health scienceseducation.field_of_studyVenous ThromboembolismHematologyMiddle AgedThrombosisPhenotypePulmonary embolismProteomeN-AcetylgalactosaminyltransferasesFemaleAdultQuantitative Trait LociImmunologyPopulationInterferon-gamma03 medical and health sciencesInterleukin-15 Receptor alpha SubunitmedicineHumansGlial Cell Line-Derived Neurotrophic FactoreducationAged030304 developmental biologybusiness.industryPulmonary SurfactantsCell BiologyAtherosclerosismedicine.diseaseOxidative StressGene Expression RegulationPulmonary EmbolismTranscriptomebusinessAcute-Phase ProteinsFollow-Up StudiesBlood
researchProduct

Anticoagulant drugs in noncompaction: A mandatory therapy?

2008

BACKGROUND: Noncompaction of left ventricular myocardium is a rare congenital cardiomyopathy resulting from an incomplete myocardial morphogenesis that leads to the persistence of the embryonic myocardium. This condition is characterized by a thin compacted epicardial and an extremely thickened endocardial layer with prominent trabeculations and deep intertrabecular recesses. It is not clear, in noncompaction of myocardium, whether intertrabecular recesses could be responsible for thrombi formation and thromboembolic complications. METHODS: The prevalence of stroke and echocardiographic finding of thrombus was evaluated in a continuous series of 229 patients (men and women) affected by nonc…

MaleRegistrieTime FactorsEmbolismAdministration OralHeart VentricleRisk FactorsRegistriesStrokeIschemic strokeAnticoagulantCongenital cardiomyopathyGeneral MedicineMiddle AgedStrokeAnticoagulant drugsCardiologycardiovascular systemFemaleAnticoagulant drugs noncompactionCardiomyopathiesCardiology and Cardiovascular MedicineHumanAdultHeart Defects Congenitalmedicine.medical_specialtyStroke etiologyTime Factormedicine.drug_classIsolated left ventricular noncompactionHeart Ventriclesanticoagulant; embolism; ischemic stroke; Isolated left ventricular noncompactionInternal medicineThromboembolismmedicineHumanscardiovascular diseasesThrombusNoncompactionCardiomyopathiebusiness.industryRisk FactorAnticoagulantAnticoagulantsInfantmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareEmbolismIschemic strokeThrombuLeft ventricular myocardiumbusiness
researchProduct